AccuStem Sciences, Inc. (ACUT)
| Previous Close | 0.3880 |
| Open | 0.3500 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.3880 - 0.3880 |
| 52 Week Range | 0.2707 - 1.9500 |
| Volume | |
| Avg. Volume | 2,085 |
| Market Cap | 4.402M |
| Beta (5Y Monthly) | 2.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the execution of an agreement wherein both companies will jointly manage scientific operations and R&D for AccuStem’s product portfolio. Initial plans as part of the collaboration will be to immediately focus on furthe
- GlobeNewswire
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs further agreement with the IEO, one of the most renowned comprehensive cancer centers in Europe. This important milestone will support the company’s strategic vi
- ACCESSWIRE
Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc.
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on AccuStem Sciences Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. The Goldman report carries a price target.
